Precigen: Specialist in Immunotherapies Secures US Market Exclusivity for PAPZIMEOS Until 2032!
Reading Time: 3 minutes
Precigen has secured the first and only FDA-approved therapy for the treatment of recurrent respiratory papillomatosis (RRP) in adults with PAPZIMEOS. With US market exclusivity until 2032, the peak sales potential exceeds 1 billion USD. H.C. Wainwright expects more than a doubling of the stock price. PAPZIMEOS revenues sequentially increased by over 535%. Growth is expected to accelerate further in Q2. The P/E ratio for 2028 is at 7.4. Precigen (PGEN) is a biopharmaceutical company focused on the development of innovative immune...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
